Spiridon Papapetropoulos MD, PhDphydatabase.med.miami.edu/Documents/CV/SPapapetr… · Web viewAssociate Professor of Neurology, ... Microsoft Word, Excell 2003/ Avadis, Strand

Spyridon (Spyros) Papapetropoulos MD, PhD

University of Miami, Miller School of Medicine

[email protected]

Associate Professor of NeurologyDivision of Movement DisordersDepartment of Neurology1501 NW 9th Avenue Room 2017Miami, FL 33136

Tel: (+1)(305) 243-8461Fax: (+1)(305) 243-3321

Cell: (+1) (786) 201-8066

Work Experience: Associate Professor of Neurology, Department of Neurology, University of

Miami, Leonard Miller School of Medicine2007-

Assistant Professor of Neurology, Department of Neurology, University of Miami, Leonard Miller School of Medicine

2005 – 2007

Visiting Assistant Professor of Neurology, Department of Neurology, University of Miami, Leonard Miller School of Medicine

2003 – 2004

Resident - Department of Neurology, Regional University Hospital of Patras, Greece

2001 – 2003

Honorary Clinical Assistant, Movement Disorders Section - The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

2000 – 2001

Resident in Internal Medicine - General County Hospital of Pyrgos, Greece 1999 – 2000

Intern - Patras General Regional Hospital "Saint Andreas", Achaia, Greece 1998 – 1999

Professional Affiliations/ Titles:

Director of Research, Division Of Movement Disorders, Department of Neurology, University of Miami, Miller School of Medicine.

Director of the Patras Parkinson’s disease DNA Bank Leading Member of the Global Genetics Consortium for Parkinson’s disease (GEO-PD) Member of the scientific board and clinical consultant of the University of Miami Brain

Endowment BankTM. Member of the American Academy of Neurology (AAN) Member of the Movement Disorders Society (MDS) Member of the Society for Neuroscience (SfN) Member of the Greek Neurological Society Board Certified in Neurology in the European Union (EU)

Education:

S. Papapetropoulos MD, PhD

1

mailto:[email protected]

Degree InstitutionMedical Degree (MD)- top of the Class of ‘97

University of Patras, School of Health Sciences, Faculty of Medicine, Greece

1997

Doctorate (PhD)- with Honors University of Patras, School of Health Sciences, Faculty of Medicine, Greece

2001

Research/Business Skills:

Neurogenomics/Translational Neurosciences Gene Expression Profiling/ Neurochemical Pathway Analysis/ Drug target

identification Clinical descriptive studies/ Case ascertainment/ Clinical Database Management Clinical Trial organization/supervision Research Proposal/manuscript/research report preparation BioMedical Statistics Neuropathology Human resources management

Additional:

Languages: Fluent in English, Greek and FrenchGrowing knowledge of Spanish, Italian

Software: Selected research relevant list: Microsoft Word, Excell 2003/ Avadis, Strand Genomics Pvt LtD, Bangalore, India/ SPSS 11.0 Lead Tech Inc, Chicago, Illinois/ SigmaPlot, SPSS Inc/ Adobe Photoshop, BioExpressTM CNS Suite, Genelogic Inc/ Pathway Studio, Ariadne Genomics Inc Rockville, MD.

Peer-reviewed publications:

1. S Papapetropoulos , JR Jagid, A Guevara-Salcedo, C Singer, BV Gallo. Staged unilateral or bilateral STN-DBS? Mov Disord. 2007 in press.

2. M Eisa, S Papapetropoulos, Carlos Singer, B Jabbari. Treatment of painful legs, moving toes with botulinum toxin type A injections. European Neurology 2007-in press.

3. S Papapetropoulos , A Tzakis, C Sengun, C Reddy MD, K Boukas, J Zitser, C Singer. A case of pediatric acquired chronic hepatocerebral degeneration. Pediatric Neurology 2007-in press.

4. BK Scanlon, H Katzen, BE Levin, C Singer, S Papapetropoulos. A formula for the conversion of UPDRS-III scores to Hoehn and Yahr stage. Parkinsonism and related Disorders 2007-in press).

5. S Papapetropoulos , AA Argyriou. Painful Limbs Moving Extremities (PLME). Acta Neurol Scand. 2007 Oct 10; [Epub ahead of print]

6. S Papapetropoulos , J Jagid, C Sengun, C Singer, B Gallo. Objective monitoring of tremor and bradykinesia during deep brain stimulation of STN for Parkinson’s disease: A pilot study. (Neurology, 2007) (in press).


2

7. S Papapetropoulos , N Adi, L Shehadeh, N Bishopric MD, C Singer, AA Argyriou, E Chroni. Is the G2019S LRRK2 mutation common in all southern European populations? (2007 Journal of Clinical Neuroscience) (in press).

8. S Papapetropoulos , AA Argyriou, G Mitsi, E Chroni. The G2019S LRRK2 mutation is uncommon amongst Greek patients with familial Parkinsons disease. Eur J Neurol. 2007 Nov;14(11): e6

9. Papapetropoulos S , Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus sporadic Parkinson's disease. Neurodegener Dis. 2007;4(6):424-7.

10. Papapetropoulos S , Argyriou AA, Polychronopoulos P, Chroni E. Frontotemporal and striatal SPECT abnormalities in a patient with Myoclonus-Dystonia Syndrome (MDS). (2007 Neurodegenerative diseases) (in press).

11. S Papapetropoulos , S Baez, J Zitser, C Sengun, C Singer Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. Eur Neurol. 2007 Oct 4;59(1-2):71-75

12. S. Papapetropoulos , A Rapoport, R Guilad, A Eilam, Y Lampel, C Singer; M Sadeh. Moving fingers associated with Dupuytren's Disease. Eur Neurol. 2007 Oct 11;59(1-2):96-97

13. AG Papatsoris, S Papapetropoulos, C Singer, C Deliveliotis. Urinary and erectile dysfunction in Multiple System Atrophy (MSA). Neurourol Urodyn. 2007 Jun 11; [Epub ahead of print]

14. S Papapetropoulos, J Friedman, C Blackstone, GI Kleiner, C Singer. Progressive neurodegenerative syndrome in a patient with primary immunodeficiency. Mov Disord. 2007 Aug 15;22(11):1664-6.

15. S Papapetropoulos , D McCorquodale. Optimizing human postmortem brain tissue gene expression profiling in Parkinson’s disease: From target “fishing” to translational breakthroughs. J Neurosci Res. 2007 May 14; [Epub ahead of print]

16. SJ Lincoln, OA. Ross, NM. Milkovic, DW. Dickson, A Rajput, CA. Robinson, ML. Rajput, S Papapetropoulos, DC. Mash & MJ. Farrer. Quantitative PCR based screening of -Synucleinα multiplication in multiple system atrophy. Parkinsonism Relat Disord. 2007 Feb 7; [Epub ahead of print]

17. S. Papapetropoulos. Is there a role for naturally-occurring cyanobacterial toxins in neurodegeneration? The -MAA paradigm. Neurochem Int. 2007 Jan 14; [Epub ahead ofβ print]

18. TG Lesnick, S Papapetropoulos, DC Mash, J Ffrench-Mullen, M de Andrade, JR. Henley, WA Rocca, JE Ahlskog, DM Maraganore. A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson's disease. PLoS Genet. 2007 Jun 15;3(6):e98

19. S Papapetropoulos , N Adi, L Shehadeh, DC Mash, N Bishopric. Expression Of α-Synuclein mRNA in Parkinson’s disease. Mov Disord. 2007 May 15;22(7):1057-9.

20. S Papapetropoulos , MJ Farrer, JT Stone, NM Milkovic, OA Ross, L Calvo, D McQuorquodale & Deborah C. Mash. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett. 2007 Mar 6;414(2):141-4

21. S Papapetropoulos , C Singer. Eating dysfunction associated with oromandibular dystonia: Clinical characteristics and treatment considerations. Head Face Med. 2006 Dec 7;2:47.

22. S Papapetropoulos , D McCorquodale. Gene Expression Profiling in Parkinson’s disease: Discovery of valid biomarkers, molecular targets and biochemical pathways. Future Neurol (2007) 2(1) 29-38.

23. S Papapetropoulos , C Singer. Botulinum toxin in Movement Disorders. Semin Neurol. 2007 Apr;27(2):183-94.

24. Papapetropoulos S , Tuchman A, Laufer D, Papatsoris AG, Papapetropoulos N, Mash DC. Causes of death in Multiple System Atrophy. J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):327-9


3

25. Papapetropoulos S , Papapetropoulos N, Singer C. Primary cranio-cervical dystonia presenting as a respiratory emergency. Neurology. 2007 Jan 30;68(5):388-9.

26. S Papapetropoulos , DC Mash. Motor fluctuations and dyskinesias in advanced/end stage Parkinson’s disease: a study from a population of brain donors. J Neural Transm. 2007 Mar;114(3):341-5

27. LI Golbe, G Di Iorio, K Markopoulou, A Athanassiadou, S Papapetropoulos, RL.Watts, JM. Vance, V Bonifati, TA. Williams, JR Spychala, S Stenroos, WG Johnson. Glutathione S-transferase polymorphisms and onset age in -synuclein A53T mutant Parkinson’s disease.α American Journal of Medical Genetics 2006 2006 Oct 10; [10.1002/ajmg.b.30450]

28. S Papapetropoulos, J ffrench-Mullen, D McCorquodale, Y Qin, J Pablo, DC Mash. Multiregional gene expression profiling identifies MRPS6 as a candidate gene for Parkinson’s disease. Gene Expr. 2006;13(3):205-15.

29. S Papapetropoulos , A Tuchman, D Laufer, DC Mash. Hallucinations in Multiple System Atrophy. Parkinsonism Relat Disord. 2007 Apr;13(3):193-4.

30. S Papapetropoulos , DS Lundy, RR Casiano, C Singer. Laryngeal dystonia as a presenting symptom of young-onset Parkinson’s disease. Movement Disorders (10.1002/mds.21184)

31. C Singer, S Papapetropoulos, G Uzcategui, L Vela. Efficacy and tolerability of Amantadine: A retrospective review of old and new indications. Journal of Applied Research 6 (3) 2006 240-245.

32. C Singer, S Papapetropoulos, Ram Ayyar, Ashok Verma. Botulinum toxin type A therapy in a patient with cervical dystonia and amyotrophic lateral sclerosis. Movement Disorders (in press 2007)

33. S Papapetropoulos , C Singer. Sporadic Geniospasm: Report of a case. Mov Disord. 2007 Feb 15;22(3):434

34. S Papapetropoulos , C Singer. Bilateral mirror writing movements (mirror dystonia) in a patient with writer's cramp: Functional correlates. Mov Disord. 2007 Jan;22(1):149

35. DM Maraganore, M de Andrade, A Elbaz, MJ Farrer, JP Ioannidis, R Krüger, WA Rocca, NK. Schneider, TG. Lesnick, SJ Lincoln, MM Hulihan, JO Aasly, T Ashizawa, MC Chartier-Harlin, H Checkoway, C Ferrarese, G Hadjigeorgiou, N Hattori, H Kawakami, JC Lambert, T Lynch, GD Mellick, S Papapetropoulos, A Parsian, A Quattrone, O Riess, EK Tan, C Van Broeckhoven. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA. 2006 Aug 9;296(6):661-70.

36. S Papapetropoulos, C Singer. Treatment of Primary Writing Tremor (PWT) with botulinum toxin type A injections: Report of a case series. Clin Neuropharmacol. 2006 Nov-Dec;29(6):364-7.

37. S Papapetropoulos , DC Mash. Insular pathology in Parkinson's disease patients with orthostatic hypotension. Parkinsonism Relat Disord. 2007 Jul;13(5):308-11.

38. S Papapetropoulos, M Basile, DC Mash. Dopaminergic innervation of the human striatum in Parkinson’s disease. Mov Disord. 2007 Feb;22(2):286-8

39. S Papapetropoulos , C Singer. Cervical dystonia as a presenting symptom of Parkinson's disease. Parkinsonism Relat Disord. 2006 Dec;12(8):514-6..

40. S Papapetropoulos , C Singer. A case of painless arms/moving fingers responsive to botulinum toxin A injections. Parkinsonism and Related Disorders 2007 Feb;13(1):55-6.

41. S Papapetropoulos, JM Villar, DC Mash. Is ischemic cerebrovascular disease a risk factor for dementia in patients with Parkinson’s disease?” Acta Neurol Scand. 2006 May;113(5):353-4.

42. S Papapetropoulos , C Singer, O. Ross, M. Toft, MJ. Farrer, D.C. Mash. Clinical heterogeneity of Lrrk2 G2019S. Arch Neurol. 2006 Sep;63(9):1242-6.


4

43. PA Cox, SA Banack; S Murch; A Bell; P Nunn; W Bradley; D Mash; S Papapetropoulos; et al. Lack of β-methylamino-L-alanine in brain from controls, AD, or Chamorros with PDC. Neurology 2005 (e-letter).

44. AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, P Polychronopoulos, MD1; HP. Kalofonos. Paclitaxel-induced peripheral neuropathy: Could really vitamin E supplementation prevent it? J Pain Symptom Manage. 2006 Sep;32(3):237-44.

45. P. Polychronopoulos, AA Argyriou; S. Papapetropoulos, P. Gourzis, G. Rigas, E. Chroni. Wilson’s disease and Benign Partial Epilepsy with Centrotemporal (or Rolandic) Spikes: report of a case. 2005 Epilepsy and Behavior; 2006 Mar;8(2):438-41.

46. S. Papapetropoulos. Drug-Induced Psychosis in Parkinson Disease: Phenomenology and Correlations among psychosis rating instruments. Clinical Neuropharmacology 2006 Jan-Feb;29(1):59.

47. S. Papapetropoulos, J. Gonzalez, L. Jean-Gilles, D.C. Mash. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with malignant visual hallucinations. Parkinsonism Relat Disord. 2006 May;12(4):253-6.

48. A.G. Papatsoris, Ch. Deliveliotis, C. Singer, S. Papapetropoulos. Erectile dysfunction in Parkinson’s disease. Journal of Urology 2006 2006 Mar;67(3):447-51

49. S. Papapetropoulos , D.C. Mash. Visual Hallucinations in Progressive Supranuclear Palsy (PSP). European Neurology 2005;54(4):217-9.

50. S Papapetropoulos , C Singer. Painless legs moving toes in a patient with Wilson’s disease. Mov Disord. 2006 Apr;21(4):579-80.

51. O. Ross, M. Toft, J.L. Johnson, D.C. Mash, S Papapetropoulos, I. Litvan, M.F. Gordon, MJ. Farrer & DW. Dickson. Lrrk2 and Lewy body disease. Annals of Neurology 2006 Feb;59(2):388-93.

52. Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, Kalofonos HP. Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation. J Pain Symptom Manage. 2006 Sep;32(3):237-44.

53. AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, P Polychronopoulos, H Kalofonos A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results.. Support Care Cancer. 2006 Nov;14(11):1134-40.

54. S Papapetropoulos , C Singer. Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol. 2006 Apr;253(4):535-6.

55. S Papapetropoulos , C Singer. Primary Focal Lingual Dystonia. Mov Disord. 2006 Mar;21(3):429-30.

56. S. Papapetropoulos, A.A. Argyriou, E. Chroni. No correlation between the clinical severity of autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced Parkinson’s disease. Mov Disord. 2006 Mar;21(3):430-1.

57. S Papapetropoulos , JM Villar, J Gonzalez, DC Mash. Disparities in death certificates of Parkinson’s disease patients: a report from a population of brain donors. Mov Disord. 2006 Oct;21(10):1791-2

58. Argyriou AA, Chroni E, Polychronopoulos P, Argyriou K, Papapetropoulos S, Corcondilas M, Lepoura N, Heras P. Headache characteristics and brain metastasis prediction in cancer patients. Eur J Cancer Care (Engl). 2006 Mar;15(1):90-5.

59. Argyriou AA, Koutras A, Polychronopoulos P, Papapetropoulos S, Iconomou G, Katsoulas G, Makatsoris T, Kalofonos HP, Chroni E. The impact of paclitaxel or cisplatin-based chemotherapy on sympathetic skin response: a prospective study. Eur J Neurol. 2005 Nov;12(11):858-61.


5

60. Papapetropoulos S , Ellul J, Argiriou AA, Chroni E, Lekka N. Effects of depression on the clinical phenotype of Parkinson's disease: A registry-based, case-control study. Clin Neurol Neurosurg. 2006 Jul;108(5):465-9.

61. S Papapetropoulos , C Singer. Lower Limb Post-Immobilization Dystonia in Parkinson’s disease. Journal of Neurological Sciences. 2005 Dec 15;239(1):111-4.

62. S Papapetropoulos , C Singer. A comparison of jaw-closure and jaw-opening idiopathic oromandibular dystonia. Parkinsonism and Related Disorders 2006 Mar;12(2):115-8.

63. S Papapetropoulos , C Singer. Adult-Onset Isolated Primary Focal Foot Dystonia. 2005 Parkinsonism and Related Disorders. 2006 Jan;12(1):57-60.

64. S Papapetropoulos , C Singer. Lower Facial and neck dystonia after a cosmetic surgical procedure: report of a case. Movement Disorders 2006 Jan;21(1):125-126.

65. Gourzis P, Polychronopoulos P, Papapetropoulos S, Asimakopoulos K, Beratis S. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics. Clin Neuropharmacol 2005;28(4):195-196.

66. S Papapetropoulos , Carlos Singer, D McCorquodale J Gonzalez, DC Mash. Cause, Seasonality of Death and Co-Morbidities in Progressive Supranuclear Palsy (PSP). 2005 Parkinsonism and Related Disorders. 2005 Nov;11(7):459-63.

67. C Singer, S Papapetropoulos, L Vela. Use of Mirror Dystonia as Guidance for Injection of Botulinum Toxin in Writing Dysfunction. J Neurol Neurosurg Psychiatry 2005 Nov;76(11):1608-9.

68. S Papapetropoulos, C Singer. Tardive Dystonia Associated with Ziprasidone. Am J Psy 2005 Nov;162(11):2191

69. S Papapetropoulos . Regional alpha-synuclein aggregation, dopaminergic dysregulation and the development of psychotic symptoms in Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences 2006;Spring 18(2):149-57.

70. S Papapetropoulos , J Gonzalez, DC Mash. Natural history of Progressive Supranuclear Palsy (PSP). A clinico-pathologic study from a population of brain donors. Eur Neurol 2005;54(1):1-9.

71. C Singer, S Papapetropoulos, O Farronay. Childhood-onset Hemifacial Spasm: Successful treatment with Botulinum Toxin and Review of the Literature. Pediatric Neurology 2004; 2005 Sep;33(3):220-2.

72. C Singer, D Lorenzo, S Papapetropoulos, A Mesa, B Bowen. Extrapontine myelinolysis associated with an eating disorder. Neurology 2005;64(12):2156-7.

73. C Singer, S Papapetropoulos, NI Spielholz. Primary Writing Tremor: Successful treatment with botulinum toxin injections. Clinical, pathophysiological and therapeutic observations. Movement Disorders 2005 Oct;20(10):1387-8.

74. S Papapetropoulos, C Singer. Primary writing tremor and writer’s cramp are different nosologic entities J Neurol Neurosurg Psychiatry 2005; (e-letter)

75. Papapetropoulos S , Mash DC. Psychotic symptoms in Parkinson's disease: from description to etiology. J Neurol. 252(7): p. 753-64.

76. Papapetropoulos S , Singer C. Management of the Extrapyramidal Syndrome in Chronic Acquired Hepatocerebral Degeneration (CAHD). Mov Disord 2005;20(8):1088-1089.

77. Papapetropoulos S , Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. J Neurol 2005 Oct;252(10):1223-8

78. S. Papapetropoulos , DC Mash. Alpha-synuclein aggregation and its relation to neurodegenerative diseases. Ann Neurol. 57(4): 605


6

79. S. Papapetropoulos , A. Lieberman, J. Gonzalez, D.C. Mash. Can Alzheimer’s type pathology influence the clinical phenotype of Parkinson’s disease? Acta Neurol Scand 2005;111(6):353-9.

80. S Papapetropoulos , R Lopez-Alberola, L Baumbach, A Russell, MA Gonzalez, C Singer. A case of maternally transmitted juvenile Huntington’s disease with a very large trinucleotide repeat. Movement Disorders 2005; Oct;20(10):1380-3.

81. Terzi A, Papapetropoulos S, Kouvelas ED. Past Tense Formation and Comprehension of Passive Sentences in Parkinson’s disease: Evidence from Greek. Brain and Language 2005; Sep;94(3):297-303.

82. Papapetropoulos S , Singer C. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol. 2006 Aug;13(8):e1.

83. S. Papapetropoulos , C. Singer, J.M. Villar, J. Gonzalez, D.C. Mash. Does cigarette smoking provide clinically significant neuroprotection among patients diagnosed with Parkinson’s disease? Mov Disord. 20(5):641-2.

84. S. Papapetropoulos , D.C Mash. The neurochemical mechanism of rebound psychosis in Parkinson’s disease. Mov Disord. 20(4):515.

85. Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients. Eur J Cancer Care (Engl) 2005;14(2):108-12.

86. Argyriou AA, Polychronopoulos P, Ellul J, Papapetropoulos S, Andriopoulos I, Katsoulas G, et al. Clinical and epidemiological features of motor neuron disease in southwestern Greece. Acta Neurol Scand. 111(2):108-13.

87. C Singer, S Papapetropoulos, MA Gonzalez, A Lieberman. Rimantadine in Parkinson’s disease patients experiencing peripheral adverse effects from Amantadine: Report of a case series. Mov Disord. 20(7): p. 873-877.

88. Papapetropoulos S , Scaravilli T, Morris H, An SF, Henderson DC, Quinn NP, et al. Young onset limb spasticity with PSP-like brain and spinal cord NFT-tau pathology. Neurology 2005;64(4):731-3.

89. Papapetropoulos S , Lieberman A, Gonzalez J, Singer C, Laufer D, Mash DC. Family history of dementia: dementia with lewy bodies and dementia in Parkinson's disease. J. Neuropsychiatry and Clinical Neurosciences 2006 Winter;18(1):113-6.

90. Papapetropoulos S , Gonzalez J, Mash DC. The effect of ischemic cerebrovascular disease on the survival duration and clinical characteristics of Parkinson's disease. A post-mortem study. Eur J Neurol; 2006 Jan;13(1):96-7

91. E Chroni, S Papapetropoulos, AA. Argyriou, T Papapetropoulos. A case of fatal progressive neuropathy. Delayed consequence of multiple bite s of a non-venomous snake. Clinical Neurology and Neurosurgery 2005 Dec;108(1):45-7.

92. Papapetropoulos S , Gonzalez J, Lieberman A, Mash DC. Dementia in Parkinson disease. Prevalence and clinical correlates from a population of brain donors. Int J Geriatr Psychiatry. 20(5):418-22.

93. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;64(1):26-31.

94. Papapetropoulos S , Argiriou AA. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients. Parkinsonism Relat Disord. 11(4):265-6.


7

95. Papapetropoulos S , Argyriou AA, Liossis SN, Daousis D, Katsoulas G, Apostolopoulos D, et al. A case of L-dopa-responsive parkinsonian syndrome after low-dose oral methotrexate intake. Clin Neuropharmacol 2004;27(2):95-98.

96. Papapetropoulos S, Ellul J, Polychronopoulos P, Chroni E. A registry-based, case–control investigation of Parkinson’s disease with and without cognitive impairment. Eur J Neurol 2004;11:347–351.

97. Papapetropoulos S , Argyriou AA, Ellul J, Chroni E. Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease. Eur J Neurol 2004;11(2):115-119.

98. Papapetropoulos S , Ellul J, Argyriou AA, Talelli P, Chroni E, Papapetropoulos T. The effect of vascular disease on late onset Parkinson's disease. Eur J Neurol 2004;11(4):231-235.

99. Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004;55(4):512-521.

100. Georgopoulos NA, Papapetropoulos S, Chroni E, et al. (2004) Spinocerebellar ataxia and hypergonadotropic hypogonadism associated with familial sensorineural hearing loss. Gynecol Endocrinol (19): 105-110

101. Chroni E, Papapetropoulos S, Gioldasis G, Ellul J, Diamadopoulos N, Papapetropoulos T. Guillain-Barre syndrome in Greece: seasonality and other clinico-epidemiological features. Eur J Neurol 2004;11(6):383-388.

102. Argyriou AA, Papapetropoulos S, Polychronopoulos P, Corcondilas M, Argyriou K, Heras P. Psychosocial effects and evaluation of the health-related quality of life in patients suffering from well-controlled epilepsy. J Neurol 2004;251(3):310-313.

103. Papapetropoulos S , Ellul J, Paschalis C, Athanassiadou A, Papadimitriou A, Papapetropoulos T. Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur J Neurol 2003;10(3):281-286.

104. Papapetropoulos S , Argiriou AA, Ellul J. Clinical characteristics of late-onset Parkinson disease. Arch Neurol 2003;60(12):1815-1816;

105. Chroni E, Thomopoulos C, Papapetropoulos S, Paschalis C, Karatza CL. A case of relapsing Guillain-Barre syndrome associated with exacerbation of chronic hepatitis B virus hepatitis. J Neurovirol 2003;9(3):408-410.

106. Papapetropoulos S , Paschalis C, Athanassiadou A, Ellul J, Papapetropoulos T. No male predominance in alpha-synuclein PD but the affected female fetus might be less viable, Authors reply. J Neurol Neurosurg Psychiatry 2002;72:274-280.

107. Papapetropoulos S , Paschalis C, Ellul J, Papapetropoulos T, Athanassiadou A. Survival duration of Parkinson's disease patients living in Greece who carry the G209A alpha-synuclein mutation. Mov Disord 2002;17(4):847-848.

108. Papapetropoulos S , Paschalis C, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, et al. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70(5):662-665.

Submitted (under review) peer-reviewed publications:


8

1. Pablo JP, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Basile M, Bradley WG, and Mash DC. Neurotoxic Non-Natural,Amino Acid BMAA is present in Brains of United States Patients with Sporadic ALS and Alzheimer's disease. (PNAS 2007)

2. R Lopez-Alberola, D Lorenzo, MA Gonzalez, C Sengun, C Singer, S Papapetropoulos,, Encephalitis lethargica: a reawakening from the past. (Neurology 2007)

3. D A Nation, H L Katzen, R A Rodriguez, J A Ledon, A Capano, S Papapetropoulos, BV Gallo, J R Jagid and B E Levin. Defining Sub-Threshold Depression in Parkinson s Disease. (JNNP 2007)

4. S Delgado, S Baez, C Singer, C Sengun, WA Sheremata, S Papapetropoulos. Progressive Multiple Sclerosis with Parkinsonism, dystonia and anti-Basal Ganglia antibodies (Movement Disorders 2007).

5. Papapetropoulos S , Glynos K, Zhou Z, Argyriou AA, Orfanos SE, Papapetropoulos A. No association of the insertion/deletion polymorphism of the Angiotensin Converting Enzyme (ACE) and Parkinson's disease. (Psychiatry and Clinical Neuroscienecs 2007).

6. Argyriou AA, Papapetropoulos S, Polychronopoulos P, Chroni E. Co-occurence of menengiomas and demyelization of the central nervous system: Coincidence or interrelation? (Neurological Research 2005).

7. AA Argyriou, M Koltzenburg, P Polychronopoulos, HP Kalofonos, Spiridon Papapetropoulos, Elizabeth Chroni. Peripheral nerve damage associated with administration of taxanes in patients with cancer.

8. N Adi, L Shehadeh, AV Ramachandran, DC Mash, N Bishopric, S Papapetropoulos. Gene expression of MT1 & MT2 receptors in Parkinson’s disease human post mortem brain. (Journal of Pineal Research 2007)

9. S Papapetropoulos , AA Argyriou, J Ellul, A Guevara Salcedo, E Chroni. Transient Global Amnesia and Total Serum Cholesterol Levels. (Eur J Neurol 2007)

Abstracts & Conference proceedings:1. Papapetropoulos S , Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Paschalis

C. Specific clinical phenotype associated with alpha-synuclein Parkinson's disease in comparison to familial Parkinson's disease. J Neurol. 2000;247(Suppl. 3):III/35

2. Papapetropoulos S , Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Paschalis C. Specific clinical phenotype associated with alpha-synuclein Parkinson's disease in comparison to sporadic Parkinson's disease. Mov Disord. 2000;15(Suppl.3):191-192.

3. Papapetropoulos S , Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Paschalis C. Comparison of the clinical severity between α-Synuclein Parkinson's Disease and Familial Parkinson's Disease Patients. Park Rel Dis. 2001;7:S119

4. Papapetropoulos S , Ellul J, Talelli P, Katsoulas G, Chroni E. , Paschalis Ch. Cholesterol levels in patients with Transient Global Amnesia. Eur. J. Neur. 2002;(3) Supp2:114

5. Polychronopoulos P., Papapetropoulos S., Economou A., Paschalis C. Wilson’s disease and Benign Partial Epilepsy with Centrotemporal (or Rolandic) Spikes: report of a case. Epilepsia (2002) 43 suppl. 8, p654.

6. Papapetropoulos S , Ellul J, , Athanassiadou A, Paschalis C. Survival duration of parkinsonian patients carrying the G209A alpha-synuclein mutation living in Greece. Mov Disord (2002)17 (supp5):S38.

7. Papapetropoulos S , Argyriou A. A., Neilas I, Ellul J, Polychronopoulos P, Demographic features and clinical characteristics of viral encephalitis in soouthwest Greece: A 12 year experience. Journal of Neurology (2003) suppl 2, p747.


9

8. Talelli P, Chrisanthopoulou A, Terzis G, Gioldasis G, Papapetropoulos S, Argyriou A. A, Ellul J. Predicting severe strokes using common carotid artery intima media thickness in association with other risk factors. Journal of Neurology (2003) suppl 2, p703

9. A. Georgopoulos, S Papapetropoulos, E Chroni, ES Papadeas, PA Dimopoulos, V Kyriazopoulou, G Kourounis and VA. Tzingounis . Cerebellar ataxia and hypergonadotropic hypogonadism associated with familial sensorineural hearing loss. Journal of Neurology (2003) suppl 2, p521

10. Moutopoulou M, Argyriou AA, Katsoulas G, Papapetropoulos S, Chroni E. The effect of carpal tunnel syndrome in sympathetic skin responses recorded from the palm. Journal of Neurology (2003) suppl 2, p359

11. Polychronopoulos P, Economou A, Neilas I, Argyriou AA, Katsoulas G, Papapetropoulos S, Papapetropoulos Th. Alcohol-relatted seizures: a prospective study in a hospitalized cohort of adult patients. Journal of Neurology (2003) suppl 2, p371.

12. Papapetropoulos S , Ellul J, Argyriou AΑ, Chroni E. Positive family History has no effect on the clinical phenotype of Parkinson’s disease. 14th Conference of Southeast European Society for Neurology and Psychiatry (2003), Free Communication. Page 34.

13. P Heras, AA Argyriou, S Papapetropoulos, M Corcondilas, K Argyriou, P Polychronopoulos. Psychosocial effects and evaluation of the health-related quality of life in patients suffering from mild epilepsy. Epilepsia (2003) Vol.44 Sup. 8, p499

14. P Polychronopoulos, P Papathanasopoulos, AA Argiriou, M Giannakopoulou, S Papapetropoulos, T Papapetropoulos. Sensorineural hearing loss: A reversible effect of Vigabatrin. Epilepsia (2003) Vol.44 Sup. 8, p467

15. S Papapetropoulos , J Ellul, E Chroni1, NP Lekka. The impact of depression and antidepressant treatment on motor function of patients with idiopathic Parkinson’s disease. Annals of General Hospital Psychiatry 2003, 2(Suppl 1):S105

16. S. Papapetropoulos , J. Ellul, P. Polychronopoulos, E. Chroni, T. Papapetropoulos. A registry-based, case control investigation of Parkinson's disease with and without cognitive impairment. Mov Disord (2004)19 (supp9):[P695]

17. S. Papapetropoulos , J. Gonzalez, A. Lieberman, D.C. Mash. Dementia in Parkinson disease. Prevalence and clinical correlates in a nationwide population of brain donors. Mov Disord (2004)19 (supp9);[P539]

18. S. Papapetropoulos , J. Gonzalez, A. Lieberman, D.C. Mash. Alzheimer disease (AD) pathology in patients clinically and pathologically diagnosed with Parkinson disease (PD). Are the symptoms different?. Mov Disord (2004)19 (supp9);[P619]

19. S. Papapetropoulos , J. Gonzalez, A. Lieberman, D.C. Mash. A comparison of demented patients with pathologically confirmed Parkinson disease (PD) and Alzheimer disease (AD) pathology and non-demented patients also with confirmed Parkinson disease and Alzheimer disease. Mov Disord (2004)19 (supp9);[P693]

20. C. Singer, S. Papapetropoulos, M.A. Gonzalez, A. Lieberman, E. Roberts Rimantadine as an alternative to amantadine in Parkinson patients with severe leg edema secondary to amantadine: Case reports. Mov Disord (2004)19 (supp9);[P694]

21. T. Scaravilli, S. Papapetropoulos, H. Morris, N.P. Quinn, F. Scaravilli, K.P. Bhatia. A patient with PSP-like brain and spinal cord NFT-tau pathology presenting as young onset spastic paraplegia. Mov Disord (2004)19 (supp9);[P1006]

22. L.I. Golbe, G. Di Iorio, K.M. Markopoulou, A. Athanassiadou, S. Papapetropoulos, R.L. Watts. Glutathione S-transferase P1 and Z1 alleles influence onset age in Parkinson's disease caused by the -synuclein A53T mutation. α Mov Disord (2004)19 (supp9);[P1072]


10

23. S. Papapetropoulos , A. Argyriou, P. Polychronopoulos, P. Gourzis, T. Spiridonidis, S. Salakou, V. Sirrou, P. Papathanasopoulos: Myoclonus-dystonia syndrome associated with psychiatric disorders and findings in the brain perfusion SPECT. Journal of Neurology 2004; 251 (suppl III): 66

24. S. Papapetropoulos , A. Argyriou, S. Liossis, D. Daousis, G. Katsoulas, D. Apostolopoulos, E. Chroni: Parkinsonian syndrome as a side effect of oral methotrexate intake: case report. Journal of Neurology 2004; 251 (suppl III):67

25. A. Argyriou, P. Polychronopoulos, I. Andriopoulos, S. Papapetropoulos, G. Katsoulas, J. Ellul, S. Salakou, E. Chroni: Epidemiological features of motor neuron disease in southwestern Greece. Journal of Neurology 2004; 251 (suppl III):154

26. Argyriou, P. Polychronopoulos, I. Andriopoulos, S. Papapetropoulos, G. Katsoulas, J. Ellul, S. Salakou, E. Chroni: Clinical features of motor neuron disease in southwestern Greece. Journal of Neurology 2004; 251 (suppl III):154

27. A. Argyriou, G. Katsoulas, S. Papapetropoulos, P. Talleli, M. Aplada, K. Stavropoulou, V. Sirrou, V. Huliara, I. Andriopoulos, E. Gourzoulidou, C. Dimitropoulou and J. Ellul Announcement and preliminary results of a randomized controlled study comparing the position of the bevel of the needle in the prevention of headache after a diagnostic lumbar puncture. European Journal of Neurology 11 (Suppl. 2), P1230

28. A. A. Argyriou, P. Polychronopoulos, S. Papapetropoulos, J. Ellul, G. Katsoulas, S. Salakou and E. Chroni. Clinical and epidemiological features of ALS in Southwestern Greece. European Journal of Neurology 11 (Suppl. 2), P2568

29. S. Papapetropoulos, A.A. Argyriou, J. Ellul. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. Movement Mov Disord (2005) 20 (suppl0);[P172]

30. S. Papapetropoulos , R. Lopez-Alberola, L. Baumbach, A. Russell, M.A. Gonzalez, C. Singer A case of maternally transmitted juvenile Huntington’s disease (HD) with a very large trinucleotide repeat. Mov Disord (2005) 20 (supp10);[P116]

31. S. Papapetropoulos , A.A. Argyriou, E. Chroni. No correlation between the clinical severity of autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced Parkinson’s disease. Mov Disord (2005) 20 (supp10);[P173]

32. S. Papapetropoulos , C. Singer. Management of the extrapyramidal syndrome in acquired chronic hepatocerebral degeneration (ACHD). Mov Disord (2005) 20 (supp10);[P190]

33. S. Papapetropoulos , J.M. Villar, C. Singer, J. Gonzalez, D.C. Mash. Smoking among patients diagnosed with Parkinson’s disease: Is it neuroprotective? Mov Disord (2005) 20 (supp10);[P395]

34. C. Singer, S. Papapetropoulos, N. Spielholtz. Primary writing tremor successfully treated with botulinum toxin injections: Report of two cases. Mov Disord (2005) 20 (supp10);[P564]

35. S. Papapetropoulos , A. Argyriou, P. Polychronopoulos, E. Chroni. Fatal progressive neuropathy as a delayed consequence of multiple bites from a non-venomous snake 15 th

Meeting of the European Neurological Society (ENS), Vienna, Austria, 18-22 June 2005. J Neurol 2005; 252(suppl 2): 157

36. P. Gourzis, P. Polychronopoulos, A. Argyriou, S. Papapetropoulos, K. Assimakopoulos, S. Beratis. Quetiapine treating focal tardive dystonia resulting from administration of atypical antipsychotics. 15th Meeting of the European Neurological Society (ENS), Vienna, Austria, 18-22 June 2005. J Neurol 2005; 252(suppl 2): 145

37. AA. Argyriou, P. Polychronopoulos, A. Koutras, G. Iconomou, S. Papapetropoulos, G. Katsoulas, N. Lepoura, HP. Kalofonos, E. Chroni. Randomized controlled trial of vitamin E supplementation for protection against cisplatin and paclitaxel-induced peripheral nerve


11

damage. 9th Congress of the European Federation of Neurological Societies (EFNS), Athens, Greece, 17-20 September 2005. Eur J Neurol 2005

38. AA. Argyriou, M. Partheni, P. Polychronopoulos, S. Papapetropoulos, D. Konstantinou, E. Chroni. Co-occurrence of meningiomas and demyelination of the central nervous system: coincidence or interrelation? Report of two cases. 9th Congress of the European Federation of Neurological Societies (EFNS), Athens, Greece, 17-20 September 2005. Eur J Neurol 2005

39. C. Singer, S. Papapetropoulos. Adult-onset primary focal foot dystonia. Park Rel Dis 2005; (supp 2) 11:p119

40. D.C. Mash, Y. Qin, Q. Ouyang, S. J. Pablo, S. Papapetropoulos, M. J. Basile. Cocaine abuse triggers abnormal expression of alpha-synuclein expression in DA cell bodies and terminals. American Academy of Neurology, 57th annual meeting (2005 Miami Beach, FL)

41. C. Singer, S. Papapetropoulos. Post-Immobilization Dystonia in Parkinson s Disease American Academy of Neurology, 57th annual meeting (2005 Miami Beach, FL)

42. C. Singer, S. Papapetropoulos. A comparison of jaw-closure and jaw-opening idiopathic oromandibular dystonia. 130th Annual Meeting of the American Neurological Association in San Diego, California, September 25-27, 2005.

43. S. Papapetropoulos, J. Gonzalez, L. Jean-Gilles, D.C. Mash. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with malignant visual hallucinations. 130th Annual Meeting of the American Neurological Association in San Diego, California, September 25-27, 2005.

44. S. Papapetropoulos , C. Singer. Dysphagia associated with focal oromandibular dystonia. 130th Annual Meeting of the American Neurological Association in San Diego, California, September 25-27, 2005.

45. S. Papapetropoulos, J. Gonzalez, L. Jean-Gilles, D.C. Mash. Extranigral Lewy body density in Parkinson's disease patients with visual hallucinations. 35th Society for Neuroscience meeting 2006 in Washington DC November

46. D Maraganore, M de Andrade, A Elbaz,M Farrer, J Ioannidis, R Kruger, W Rocca, N Schneider, T Lesnick, J Aasly, T Ashizawa, MC Chartier-Harlin, H Checkoway, C Ferrarese, G Hadjigeorgiou, N Hattori, H Kawakami, T Lynch, Dublin. G Mellick, S Papapetropoulos, A Parsian, A Quattrone, O Riess, EK Tan, C Von Broeckhoven. Collaborative-pooled analysis of alpha-synuclein REP1 variability and Parkinson s disease (PD). Neurology (66);5 Supp 2 IN3.004 (page A330)

47. S Papapetropoulos , JMH ffrench-Mullen, D McCorquandale,. A Buck, P Tarighy, J Pablo, DC Mash. Finding molecular targets in Parkinson Disease: Multiregion, high-throughput gene array. Neurology (66);5 Supp 2 IN3.010 (page A332)

48. S Papapetropoulos , DC Mash. Increased insular Lewy body density in Parkinson’s disease patients with orthostatic hypotension. Neurology (66);5 Supp 2 P04.058 (page A215)

49. B. K. Scanlon, H. L. Katzen, D. A. Nation, R. A. Rodriguez, S. Papapetropoulos, C. Singer, B. V. Gallo, B. E. Levin. Neuropsychological Predictors of All-Cause Mortality in Parkinson's Disease. INS 2006

50. S.Papapetropoulos , C.Singer. Cranial dystonic syndromes as a presenting symptom of Parkinson's disease. 2006 Movement Disorders 21 (S15) P472

51. S.Papapetropoulos ; J.M.French-Mullen; D.McCorquondale; Y.Qin; N.C.Adi; J.Pablo; D.C.Mash. Multiregion, high - throughput gene expression profiling identifies novel candidate genes for Parkinson's disease. 2006 Movement Disorders 21 (S15) P666

52. S.Papapetropoulo s; D.C.Mash. Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. 2006 Movement Disorders 21 (S15) P866


12

53. S.Papapetropoulos ; M.J.Farrer; J.Stone; D.McCorquodale; L.Calvo; D.C.Mash. Phenotypic associations of tau and apoE haplotypes in Parkinson's disease. 2006 Movement Disorders 21 (S15) P92

54. S.Papapetropoulos ; C.Singer. Treatment of primary writing tremor ( PWT ) with botulinum toxin type A injections: Report of a case series. 2006 Movement Disorders 21 (S15) P1351

55. S. Papapetropoulos , J. M. Ffrench-mullen, Y. Qin, D. Mccorquodale, A. Buck, J. P. Pablo, D. C. Mash;. Multiregion, high-throughput gene expression profiling identifies mitochondrial ribosomal protein s6 (mrps6) as a candidate gene for Parkinson’s disease. 36th Society for Neuroscience meeting 2006 in Washington DC (October 15th) 173.13/GG9.

56. Nation, D. A., Scanlon, B. K., Katzen, H. L., Rodriguez, R. A., Ledon, J. A., Capano, A., Papapetropoulos, S., Singer, C., Jagid, J. R., & Levin, B. E. (2007, May). Defining features of subsyndromal depression in Parkinson’s disease. Poster session presented at the annual meeting of the American Academy of Neurology, Boston, MA.

57. Scanlon, B. K., Katzen, H. L., Nation, D. A., Rodriguez, R. A., Papapetropoulos, S., Singer, C., Gallo, B. V., & Levin, B. E. (2007, February). Neuropsychological predictors of all-cause mortality in Parkinson’s disease. Poster session presented at the annual meeting of the International Neuropsychological Society, Portland, OR

58. S Papapetropoulos , BVGallo, J Jagid, J Zitser, C Sengun, C Singer. Peri- and intra-operative electronic monitoring of tremor STN DBS for Parkinson s disease. Poster session presented at the annual meeting of the American Academy of Neurology, Boston, MA.

59. R Lopez-Alberola, S Papapetropoulos, D Lorenzo, MA Gonzalez, C Sengun, C Singer, Encephalitis lethargica: a reawakening from the past. Poster session presented at the annual meeting of the American Academy of Neurology, Boston, MA.

60. S Papapetropoulos , DM Maraganore, N Adi, J ffrench-Mullen, PhD, D McCorquodale, DC Mash. Multiregional high-throughput gene expression profiling of Braak regions in Parkinson s disease. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

61. S Papapetropoulos , N Adi, L Shehadeh, N Bishopric, C Singer, AA Argyriou, E Chroni. Is the G2019S LRRK2 mutation common in all southern European populations? The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

62. N Adi, L Shehadeh, DC Mash, C Singer, S Papapetropoulos. Expression of MT1and MT2 receptors in human postmortem amygdala and substantia nigra of Parkinson s disease and controls subjects. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

63. S Papapetropoulos , J Jagid, N Ahmad, J Zitser, C Sengun, C Singer, BV Gallo. Low rate of complications with unilateral STN-DBS in advanced Parkinson’s disease. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

64. S Papapetropoulos , N Adi, L Shehadeh, J ffrench−Mullen, N Bishopric and DC Mash. Decreased expression of alpha−synuclein in Parkinson s disease: Multiple−level evidence. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

65. S Papapetropoulos , J Jagid, C Sengun, C Singer, B V Gallo.Objective monitoring of tremor and bradykinesia during deep brain stimulation of STN for Parkinson’s disease: A pilot study. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.


13

66. S Papapetropoulos , S Baez, J Zitser, C Sengun, C Singer. Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

67. B K Scanlon, H Katzen, D A Nation, R A Rodriguez, S Papapetropoulos, J A Ledon, A Capano, D Wilensky, J Zitser, C Singer, B V Gallo, J A Jagid and B E Levin. Side and Symptom of Disease Onset is Related to Lifespan in Parkinson s Disease. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

68. D A Nation, H L Katzen, R A Rodriguez, J A Ledon, A Capano, S Papapetropoulos, B V Gallo, J R Jagid and B E Levin. Defining Features of Sub-syndromal Depression in Parkinson s Disease. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

69. S Papapetropoulos , J Friedman, C Blackstone, GI Kleiner, C Sengun, C Singer. A progressive, fatal dystonia-parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. The Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders.

70. B.E. Levin, H. Katzen, D. Nation, B. Scanlon, D. Wilensky, S. Papapetropoulos, C. Singer. C. Sengun, R. Rodriguez. Diagnosing Depression in Parkinson’s Disease: BDI Screening versus DSM-IV-TR Criteria. Twenty First Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders Movement Disorders, Vol. 22, No. 12, 2007

71. A. Tuchman, C. Sengun, A. Russell, C. Singer, S. Papapetropoulos. Anterocollis: Classification, Clinical Phenotype, Treatment Outcomes and Risk Factors. Twenty First Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders Movement Disorders, Vol. 22, No. 12, 2007 1.

72. N.C. Adi, L. Shedah, D. Mash, C. Singer, S. Papapetropoulos. Melatonin receptor expression in human postmortem amygdala and substantia nigra of Parkinson s disease and controls subjects. Society for Neuroscience, 2007 San Diego, CA.

73. S Papapetropoulos, N. Adi, L. Shehadeh, D.C. Mash. Alpha-synuclein and Septin 4 gene and protein expression in Parkinson’s disease human post mortem brains. Society for Neuroscience, 2007 San Diego, CA.

74. J.P. Pablo, S.A. Banack, P.A. Cox, T.E. Johnson, S. Papapetropoulos, W.G. Bradley, D.C. Mash. Neurotoxic non-protein amino acid BMAA in brain from patients dying with ALS and Alzheimer's Disease. Society for Neuroscience, 2007 San Diego, CA.

75. L.A. Shehadeh, N. Tsinoremas, J.M. Vance, N. Adi, S. Papapetropoulos. Melatonin receptor expression in human postmortem amygdala and substantia nigra of Parkinson s disease and controls subjects. Society for Neuroscience, 2007 San Diego, CA.

76. L.A. Shehadeh, N. Tsinoremas, J.M. Vance, N. Adi, S. Papapetropoulos. The RNA Splicer Gene SRRM2 is Differentially Expressed in Parkinson’s Disease. American Society for Human Genetics 2007 meeting, San Diego CA.

Invited Talks/Platform Presentations (selected)1. Specific Clinical Phenotype associated with alpha-synuclein Parkinson’s disease. Institute of

Neurology, Queen Square, London UK February 3rd 20012. Familial Parkinson’s disease in Greece: Clinical Phenotype. The 29th Symposium of the

European Association of Geriatric Psychiatry, November 2001, Thessaloniki, Greece3. Psychiatric Symptoms in Parkinson’s disease. University of Miami, Miller School of Medicine,

Neurology Grand Rounds Lois Pope Life, Center 7th Floor Auditorium Friday, May 7, 2004


14

4. Unusual Movement Disorders. University of Miami, Miller School of Medicine, Neurology Grand Rounds Lois Pope Life, Center 7th Floor Auditorium Friday, September 9, 2005

5. BMAA in brain tissues. BMAA: Cyanobacteria, Ecosystems, and Human Health Spring Creek Ranch, Jackson Hole, Wyoming, USA October 11–14, 2005

6. BMAA in human tissues. University of Miami, Rosenstiel School of Marine and Atmospheric Sciences. Monday December 5, 2005

7. Tauopathies and Movement Disorders: A Clinical Review. NEUROLOGICAL UPDATE 2006 January 25-28, 2006 The Alexander Hotel Miami Beach, FL

8. BMAA in Relation to Neurodegeneration. Environmental Neurotoxins and Human Health The Kampong, Coconut Grove, Florida Thursday, January 26, 2006

9. Gene expression profiling in Parkinson’s disease. Genetic Epidemiology of Parkinson’s disease 2nd Annual Meeting, 10-12 September 2006, Santorini, Greece

10. Clinical aspects of tauopathies. BMAA: Testing the Hypothesis Spring Creek Ranch, Jackson Hole, Wyoming, USA October 9–13, 2006

11. Gene expression profiling in Parkinson’s disease. University of Miami, Miller School of Medicine, Neurology Grand Rounds Lois Pope Life, Center 7th Floor Auditorium Friday, November 17, 2006

12. Clinical phenotypes of genetic forms of Parkinson’s disease. Dr. John T. Macdonald Foundation Center for Medical Genetics, GENETICS CONFERENCE, December 12, 2006

13. Gene Expression Profiling in PD: Identification of novel molecular targets using a multiregional approach. Dr. John T. Macdonald Foundation Center for Medical Genetics, GENETICS CONFERENCE, December 12, 2006

14. Gene Expression Profiling in PD, Mayo Clinic Rochester MN, December 16th 200615. ALS: What causes it? NTBG Florida Physicians’ Course. The Kampong, Coconut Grove, Florida

February 15-17, 200716. Hallucinations and psychosis in PD: Phenotypic and treatment considerations Neurology

Grand Rounds, Michigan State University 1/18/ 2007 17. Multiregional high-throughput gene expression profiling in Parkinson’s disease: the process

of novel pathway and target identification. Neuroscience Grand Rounds, Michigan State University 1/18/ 2007

18. A Video Presentation of Movement Disorder Cases. NEUROLOGICAL UPDATE 2007 January 24-27, 2007 The Alexander Hotel Miami Beach, FL

19. Animal model studies of BMAA toxicity. 4th International Symposium “ BMAA: Its occurrence and potential threat to human health”. Dalarö, Stockholm, Sweden August 20-23, 2007 Karolinska Institute, Sweden

20. Alpha-synuclein and Septin 4 gene and protein expression in Parkinson’s disease human post mortem brains. November 3rd 2007, Society for Neuroscience Meeting, San Diego, CA.

Teaching

Teaching Specialization: Neurology, Neuroscience and Movement Disorders with over 5 years of experience.8/2002-9/2003: Teaching faculty and Course Director in Behavioral Neurology. Technological Educational Institute of Patras, Greece, School Of Health And Welfare Professions, Dept. Of Speech And Language Therapy. (http://www.teipat.gr/pages/logo/logoth_eng.htm) Graduate/Undergraduate Teaching:


15

http://www.teipat.gr/pages/logo/logoth_eng.htm

Directly supervised undergraduate/graduate students during my appointment. Currently supervising research post-doctoral fellows and clinical Movement Disorders fellows. Actively involved in teaching and training of basic scientists and clinicians in the Department of Neurology. Current Teaching activities include:

1. Medical student Case-based Neurology Training conducted by the Center for Research in Medical Education (CRME) of the University of Miami, Miller School of Medicine.

2. Neurology Resident training through monthly lunch seminars in Movement Disorders.3. Movement Disorders Clinical Fellow training and supervision.

Book Chapters

S. Papapetropoulos, C. Singer. A case of seizures, orofacial dyskinesias and peripheral neuropathy. In: Movement Disorders 100 Instructive cases. Editor: R. Reich, Publisher: Informa Healthcare, Abingdon UK (2006)

Other1. Associate Editor of the Year Book of Neurology and Neurosurgery. Mosby Publishers2. Organizer of the 2nd Annual Meeting on the Genetic Epidemiology of Parkinson’s disease

(http://www.geopdmeeting2006.gr) 3. Peer reviewer for: Annals of Neurology, Neurology, Movement Disorders, European Journal

of Neurology, Journal of Neurology, Expert Review of Neurotherapeutics, Drugs & Aging, Neuroscience Letters, Biomarkers in Medicine, Marine Drugs and others.

4. Permanent resident of the USA

Research Support:

C. Research Projects Ongoing1. “The basis of psychotic symptoms in Parkinson’s disease”- Principal Investigator: Dr. Spiridon Papapetropoulos. Source/Agency: National Institute of Mental Health (NIMH).Type: R03 (PA-03-108). Period of support: 1/4/2007-31/3/2009.2. “Cyanobacterial toxin (BMAA) in postmortem brain tissue and hair samples of ALS/PD/AD patients”. Principal Investigator: Dr. Spiridon Papapetropoulos Source/Agency: Muscular Dystrophy Association (MDA) Research Department. Period of support: 2/1/2006-1/31/2008.3. “Cyanobacterial toxin (BMAA) in brain and hair tissue of AD patients”. Principal Investigator: Dr. Spiridon Papapetropoulos. Source/Agency: Alzheimer’s Association- New Investigator Grant. Period of support: 7/1/2006-1/31/2008. 4. “Peripheral blood gene expression profiling: discovery of valid biomarkers” – Principal Investigator: Spiridon Papapetropoulos. Source/Agency: University of Miami Scientific Awards Committee Research Grant. Period of Support: 9/1/2007-8/31/20085. “Weight Loss in Parkinson’s disease”- Principal Investigator: Spiridon Papapetropoulos. Source/Agency: Parkinson’s Foundation/Parkinson Study Group. Period of Support: 12/1/2007-11/31/2008

D. Completed Projects


16

http://www.geopdmeeting2006.gr/

1. "Post-mortem neurochemical investigations of visual hallucinations in Parkinson’s disease brain donors". Principal Investigator: Dr. Spiridon Papapetropoulos. Source/Agency: Stanley J. Glaser Foundation Biomedical Research Support Grant. Period of support: February 1, 2006 through January 31, 2007


17